论文部分内容阅读
目的探讨自行设计的内皮前体细胞(EPCs)释放系统体外释放EPCs的可行性和条件。材料与方法采用自行设计的EPCs释放系统(国家专利号:ZL2006200406232),将由人体外周静脉血液(40 ml)提取培养的EPCs,在不同条件下(扩张压力和注射压力)以Annexin V及PI染色测量细胞数量和存活率。结果EPCs释放系统在体外可以有效释放EPCs,数据显示充盈压<3 atm及细胞悬液的释放流率<0.3 ml/s时,释放后的EPCs的数量、细胞活性以及细胞凋亡和坏死与释放前体外相比,差异无统计学意义;释放流率0.2 ml/s及压力2.5 atm为峰值,EPCs的存活率最高。结论在一定释放压力和流率下,EPCs释放系统可以有效释放EPCs,为血管狭窄及再狭窄治疗提供一种新器械和思路。
Objective To investigate the feasibility and conditions of in vitro release of EPCs by self-designed endothelial progenitor cells (EPCs) release system. MATERIALS AND METHODS EPCs extracted from human peripheral venous blood (40 ml) were cultured in EPCs release system (National Patent No .: ZL2006200406232) and measured by Annexin V and PI staining under different conditions (dilation pressure and injection pressure) Cell number and survival rate. Results The EPCs release system could effectively release EPCs in vitro. The data showed that when the filling pressure <3 atm and the release rate of the cell suspension <0.3 ml / s, the number of EPCs, cell viability and apoptosis and necrosis There was no significant difference between pre-vitro and in vitro. The release rate of 0.2 ml / s and pressure of 2.5 atm peaked, and the survival rate of EPCs was the highest. Conclusion Under certain release pressure and flow rate, EPCs release system can effectively release EPCs, which provides a new instrument and idea for the treatment of vascular stenosis and restenosis.